Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2390-2396

  Socinski, Mark A ^a   Okamoto, I ^b   Hon, J K ^c   Hirsh, V ^d   Dakhil, S R ^e   Page, R D ^f   Orsini, J ^g   Yamamoto, N ^h   Zhang, H ⁱ   Renschler, M F ⁱ  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Clearview Cancer Institute   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e Cancer Center of Kansas   (United States)

^f Center for Cancer and Blood Disorders   (United States)

^g Essex Oncology of New Jersey   (United States)

^h SHIZUOKA CANCER CENTER   (Japan)

ⁱ CELGENE CORPORATION   (United States)

Author keywords

Histology; Nab paclitaxel; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOOT PAIN; HAND PAIN; HEARING IMPAIRMENT; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUESTIONNAIRE; RATING SCALE; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

HISTOLOGY; NAB-PACLITAXEL; NON-SMALL-CELL LUNG CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, SQUAMOUS CELL; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84883343327     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt235     Document Type: Article

References (26)

1. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2.2013.
2. Alimta (pemetrexed for injection) [package insert]. Indianapolis, IN: Lilly USA, LLC; 2013.
3. Avastin (bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2013.
4. Howlader N, Noone AM, Krapcho M et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012.
5. Cetin K, Ettinger DS, Hei YJ,, et al. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol 2011; 3: 139-148.
6. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008; 14: 4200-4205.
7. Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2: 59-64.
8. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12: 1317-1324.
9. Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension (albumin-bound) [package insert]. Summit, NJ: Celgene Corporation, 2013.
10. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non- small-cell lung cancer. J Clin Oncol 2008; 26: 639-643.
11. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007; 60: 759-766.
12. Socinski MA, Manikhas GM, Stroyako versus ky DL, et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 852-861.
13. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30: 2055-2062.
14. de Marinis F, Pereira JR, Fossella F, et al. Lung cancer symptom scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 30-36.
15. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24: 3831-3837.
16. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
17. Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 5311-5320.
18. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835-1842.
19. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
20. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
21. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
22. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
23. Wistuba II, Gazdar AF. Pathology of lung cancer. In: Syrigos K, Nutting CM, Roussos C (eds), Tumors of the Chest: Biology, Diagnosis and Management. Germany: Springer; 2006: 93-105.
24. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-1457.
25. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every- 3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 468-473.
26. Socinski MA, Ivanova A, Bakri K, et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 2006; 17: 104-109.